Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, an industry leader in artificial intelligence for drug discovery and development, today announced the appointment of Sharath Hegde, Ph.D. as its Chief ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback